Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat

Rationale Human immunodeficiency virus (HIV) infection is associated with substantial increases in generalized anxiety. The HIV regulatory protein, transactivator of transcription (Tat), has been implicated in the neuropathogenesis related to HIV-1 infection. However, direct examination of the effec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Psychopharmacology 2014-06, Vol.231 (11), p.2349-2360
Hauptverfasser: Paris, Jason J., Singh, Harminder D., Ganno, Michelle L., Jackson, Pauline, McLaughlin, Jay P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2360
container_issue 11
container_start_page 2349
container_title Psychopharmacology
container_volume 231
creator Paris, Jason J.
Singh, Harminder D.
Ganno, Michelle L.
Jackson, Pauline
McLaughlin, Jay P.
description Rationale Human immunodeficiency virus (HIV) infection is associated with substantial increases in generalized anxiety. The HIV regulatory protein, transactivator of transcription (Tat), has been implicated in the neuropathogenesis related to HIV-1 infection. However, direct examination of the effect of Tat on behavioral measures of anxiety has not been demonstrated. Objective To identify whether expression of the Tat 1-86 protein exerts dose-dependent and persistent anxiety-like effects in a whole animal model, the GT-tg bigenic mouse. Methods GT-tg mice and C57BL/6J controls were administered doxycycline in a dose- (0, 50, 100, or 125 mg/kg, i.p., for 7 days) or duration- (100 mg/kg, i.p., for 0, 1, 3, 5, or 14 days) dependent manner to induce Tat 1-86 in brain. Mice were assessed for anxiety-like behavior in an open field, social interaction, or marble burying task 0, 7, and/or 14 days later. Central expression of Tat 1-86 protein was verified with Western blot analyses. Results Doxycycline produced no effects on C57BL/6J controls that lacked the Tat 1-86 transgene. Among GT-tg mice, doxycycline (100 mg/kg for 3, 5, or 7 days) significantly increased anxiety-like behavior in all tasks, commensurate with enhanced Western blot labeling of Tat 1-86 protein in brain, displaying optimal effects with the 7-day regimen. Greater exposure to doxycycline (either 125 mg/kg for 7 days or 100 mg/kg for 14 days) impaired locomotor behavior; whereas lower dosing (below 100 mg/kg) produced only transient increases in anxiety-like behavior. Conclusions Expression of HIV-1-Tat 1-86 in GT-tg mouse brain produces exposure-dependent, persistent increases in anxiety-like behavior.
doi_str_mv 10.1007/s00213-013-3385-1
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4020990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A372250933</galeid><sourcerecordid>A372250933</sourcerecordid><originalsourceid>FETCH-LOGICAL-c636t-3ceaf00a0734b2cefa0649029e68de9ede5275a4b884fdbe12541ac76e8103193</originalsourceid><addsrcrecordid>eNp1Uk1v1DAQtRCILoUfwAVZ4tIDKeOvfFyQVhW0lSpxKVwtx5nsumTtxU6q7r_HYbelRWDLGmnmvWfP-BHylsEpA6g-JgDORAH5CFGrgj0jCyYFLzhU_DlZAIhcYao-Iq9SuoG8ZC1fkiMuheKqrBdks_R3DsddMbgfSFtcm1sXIg093TiLdBtDN1nsaLujNvjOjS54M1CLfow54t02Yko5OVPGNdKLy-8FoxFX02DGEHezxIjOf6DXZnxNXvRmSPjmEI_Jty-fr88uiquv55dny6vClqIcC2HR9AAGKiFbbrE3UMoGeINl3WGDHSpeKSPbupZ91yLjSjJjqxJrBoI14ph82utup3aD3eG1ehvdxsSdDsbppxXv1noVbrUEDk0DWeDkIBDDzwnTqDcuWRwG4zFMSTPFm0bIUlQZ-v4v6E2YYh7Sb5TkUqm6-YNamQG1833I99pZVC9FxbmCRoiMOv0HKu8O83cEj73L-ScEtifYGFKK2D_0yEDPHtF7j-jsET17RLPMefd4OA-Me1NkAN8DUi75FcZHHf1X9ReBNcZa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1524245589</pqid></control><display><type>article</type><title>Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Paris, Jason J. ; Singh, Harminder D. ; Ganno, Michelle L. ; Jackson, Pauline ; McLaughlin, Jay P.</creator><creatorcontrib>Paris, Jason J. ; Singh, Harminder D. ; Ganno, Michelle L. ; Jackson, Pauline ; McLaughlin, Jay P.</creatorcontrib><description>Rationale Human immunodeficiency virus (HIV) infection is associated with substantial increases in generalized anxiety. The HIV regulatory protein, transactivator of transcription (Tat), has been implicated in the neuropathogenesis related to HIV-1 infection. However, direct examination of the effect of Tat on behavioral measures of anxiety has not been demonstrated. Objective To identify whether expression of the Tat 1-86 protein exerts dose-dependent and persistent anxiety-like effects in a whole animal model, the GT-tg bigenic mouse. Methods GT-tg mice and C57BL/6J controls were administered doxycycline in a dose- (0, 50, 100, or 125 mg/kg, i.p., for 7 days) or duration- (100 mg/kg, i.p., for 0, 1, 3, 5, or 14 days) dependent manner to induce Tat 1-86 in brain. Mice were assessed for anxiety-like behavior in an open field, social interaction, or marble burying task 0, 7, and/or 14 days later. Central expression of Tat 1-86 protein was verified with Western blot analyses. Results Doxycycline produced no effects on C57BL/6J controls that lacked the Tat 1-86 transgene. Among GT-tg mice, doxycycline (100 mg/kg for 3, 5, or 7 days) significantly increased anxiety-like behavior in all tasks, commensurate with enhanced Western blot labeling of Tat 1-86 protein in brain, displaying optimal effects with the 7-day regimen. Greater exposure to doxycycline (either 125 mg/kg for 7 days or 100 mg/kg for 14 days) impaired locomotor behavior; whereas lower dosing (below 100 mg/kg) produced only transient increases in anxiety-like behavior. Conclusions Expression of HIV-1-Tat 1-86 in GT-tg mouse brain produces exposure-dependent, persistent increases in anxiety-like behavior.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-013-3385-1</identifier><identifier>PMID: 24352568</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Animal behavior ; Animals ; Anxiety ; Anxiety Disorders - chemically induced ; Anxiety Disorders - physiopathology ; Biomedical and Life Sciences ; Biomedicine ; Blotting, Western ; Brain ; Brain - drug effects ; Brain - physiopathology ; Complications and side effects ; Development and progression ; Dose-Response Relationship, Drug ; Doxycycline - pharmacology ; Gene Expression - drug effects ; Genetic aspects ; HIV ; HIV infection ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Male ; Mice, Inbred C57BL ; Mice, Transgenic ; Neuropsychological Tests ; Neurosciences ; Original Investigation ; Pharmacology/Toxicology ; Physiological aspects ; Proteins ; Psychiatry ; Psychological aspects ; Psychotropic Drugs - pharmacology ; Risk factors ; Rodents ; tat Gene Products, Human Immunodeficiency Virus - genetics ; tat Gene Products, Human Immunodeficiency Virus - metabolism ; Time Factors ; Viral proteins</subject><ispartof>Psychopharmacology, 2014-06, Vol.231 (11), p.2349-2360</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><rights>COPYRIGHT 2014 Springer</rights><rights>Springer-Verlag Berlin Heidelberg 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c636t-3ceaf00a0734b2cefa0649029e68de9ede5275a4b884fdbe12541ac76e8103193</citedby><cites>FETCH-LOGICAL-c636t-3ceaf00a0734b2cefa0649029e68de9ede5275a4b884fdbe12541ac76e8103193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-013-3385-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-013-3385-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24352568$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paris, Jason J.</creatorcontrib><creatorcontrib>Singh, Harminder D.</creatorcontrib><creatorcontrib>Ganno, Michelle L.</creatorcontrib><creatorcontrib>Jackson, Pauline</creatorcontrib><creatorcontrib>McLaughlin, Jay P.</creatorcontrib><title>Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat</title><title>Psychopharmacology</title><addtitle>Psychopharmacology</addtitle><addtitle>Psychopharmacology (Berl)</addtitle><description>Rationale Human immunodeficiency virus (HIV) infection is associated with substantial increases in generalized anxiety. The HIV regulatory protein, transactivator of transcription (Tat), has been implicated in the neuropathogenesis related to HIV-1 infection. However, direct examination of the effect of Tat on behavioral measures of anxiety has not been demonstrated. Objective To identify whether expression of the Tat 1-86 protein exerts dose-dependent and persistent anxiety-like effects in a whole animal model, the GT-tg bigenic mouse. Methods GT-tg mice and C57BL/6J controls were administered doxycycline in a dose- (0, 50, 100, or 125 mg/kg, i.p., for 7 days) or duration- (100 mg/kg, i.p., for 0, 1, 3, 5, or 14 days) dependent manner to induce Tat 1-86 in brain. Mice were assessed for anxiety-like behavior in an open field, social interaction, or marble burying task 0, 7, and/or 14 days later. Central expression of Tat 1-86 protein was verified with Western blot analyses. Results Doxycycline produced no effects on C57BL/6J controls that lacked the Tat 1-86 transgene. Among GT-tg mice, doxycycline (100 mg/kg for 3, 5, or 7 days) significantly increased anxiety-like behavior in all tasks, commensurate with enhanced Western blot labeling of Tat 1-86 protein in brain, displaying optimal effects with the 7-day regimen. Greater exposure to doxycycline (either 125 mg/kg for 7 days or 100 mg/kg for 14 days) impaired locomotor behavior; whereas lower dosing (below 100 mg/kg) produced only transient increases in anxiety-like behavior. Conclusions Expression of HIV-1-Tat 1-86 in GT-tg mouse brain produces exposure-dependent, persistent increases in anxiety-like behavior.</description><subject>Animal behavior</subject><subject>Animals</subject><subject>Anxiety</subject><subject>Anxiety Disorders - chemically induced</subject><subject>Anxiety Disorders - physiopathology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blotting, Western</subject><subject>Brain</subject><subject>Brain - drug effects</subject><subject>Brain - physiopathology</subject><subject>Complications and side effects</subject><subject>Development and progression</subject><subject>Dose-Response Relationship, Drug</subject><subject>Doxycycline - pharmacology</subject><subject>Gene Expression - drug effects</subject><subject>Genetic aspects</subject><subject>HIV</subject><subject>HIV infection</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Male</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Transgenic</subject><subject>Neuropsychological Tests</subject><subject>Neurosciences</subject><subject>Original Investigation</subject><subject>Pharmacology/Toxicology</subject><subject>Physiological aspects</subject><subject>Proteins</subject><subject>Psychiatry</subject><subject>Psychological aspects</subject><subject>Psychotropic Drugs - pharmacology</subject><subject>Risk factors</subject><subject>Rodents</subject><subject>tat Gene Products, Human Immunodeficiency Virus - genetics</subject><subject>tat Gene Products, Human Immunodeficiency Virus - metabolism</subject><subject>Time Factors</subject><subject>Viral proteins</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1Uk1v1DAQtRCILoUfwAVZ4tIDKeOvfFyQVhW0lSpxKVwtx5nsumTtxU6q7r_HYbelRWDLGmnmvWfP-BHylsEpA6g-JgDORAH5CFGrgj0jCyYFLzhU_DlZAIhcYao-Iq9SuoG8ZC1fkiMuheKqrBdks_R3DsddMbgfSFtcm1sXIg093TiLdBtDN1nsaLujNvjOjS54M1CLfow54t02Yko5OVPGNdKLy-8FoxFX02DGEHezxIjOf6DXZnxNXvRmSPjmEI_Jty-fr88uiquv55dny6vClqIcC2HR9AAGKiFbbrE3UMoGeINl3WGDHSpeKSPbupZ91yLjSjJjqxJrBoI14ph82utup3aD3eG1ehvdxsSdDsbppxXv1noVbrUEDk0DWeDkIBDDzwnTqDcuWRwG4zFMSTPFm0bIUlQZ-v4v6E2YYh7Sb5TkUqm6-YNamQG1833I99pZVC9FxbmCRoiMOv0HKu8O83cEj73L-ScEtifYGFKK2D_0yEDPHtF7j-jsET17RLPMefd4OA-Me1NkAN8DUi75FcZHHf1X9ReBNcZa</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Paris, Jason J.</creator><creator>Singh, Harminder D.</creator><creator>Ganno, Michelle L.</creator><creator>Jackson, Pauline</creator><creator>McLaughlin, Jay P.</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20140601</creationdate><title>Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat</title><author>Paris, Jason J. ; Singh, Harminder D. ; Ganno, Michelle L. ; Jackson, Pauline ; McLaughlin, Jay P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c636t-3ceaf00a0734b2cefa0649029e68de9ede5275a4b884fdbe12541ac76e8103193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animal behavior</topic><topic>Animals</topic><topic>Anxiety</topic><topic>Anxiety Disorders - chemically induced</topic><topic>Anxiety Disorders - physiopathology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blotting, Western</topic><topic>Brain</topic><topic>Brain - drug effects</topic><topic>Brain - physiopathology</topic><topic>Complications and side effects</topic><topic>Development and progression</topic><topic>Dose-Response Relationship, Drug</topic><topic>Doxycycline - pharmacology</topic><topic>Gene Expression - drug effects</topic><topic>Genetic aspects</topic><topic>HIV</topic><topic>HIV infection</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Male</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Transgenic</topic><topic>Neuropsychological Tests</topic><topic>Neurosciences</topic><topic>Original Investigation</topic><topic>Pharmacology/Toxicology</topic><topic>Physiological aspects</topic><topic>Proteins</topic><topic>Psychiatry</topic><topic>Psychological aspects</topic><topic>Psychotropic Drugs - pharmacology</topic><topic>Risk factors</topic><topic>Rodents</topic><topic>tat Gene Products, Human Immunodeficiency Virus - genetics</topic><topic>tat Gene Products, Human Immunodeficiency Virus - metabolism</topic><topic>Time Factors</topic><topic>Viral proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paris, Jason J.</creatorcontrib><creatorcontrib>Singh, Harminder D.</creatorcontrib><creatorcontrib>Ganno, Michelle L.</creatorcontrib><creatorcontrib>Jackson, Pauline</creatorcontrib><creatorcontrib>McLaughlin, Jay P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paris, Jason J.</au><au>Singh, Harminder D.</au><au>Ganno, Michelle L.</au><au>Jackson, Pauline</au><au>McLaughlin, Jay P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat</atitle><jtitle>Psychopharmacology</jtitle><stitle>Psychopharmacology</stitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>231</volume><issue>11</issue><spage>2349</spage><epage>2360</epage><pages>2349-2360</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>Rationale Human immunodeficiency virus (HIV) infection is associated with substantial increases in generalized anxiety. The HIV regulatory protein, transactivator of transcription (Tat), has been implicated in the neuropathogenesis related to HIV-1 infection. However, direct examination of the effect of Tat on behavioral measures of anxiety has not been demonstrated. Objective To identify whether expression of the Tat 1-86 protein exerts dose-dependent and persistent anxiety-like effects in a whole animal model, the GT-tg bigenic mouse. Methods GT-tg mice and C57BL/6J controls were administered doxycycline in a dose- (0, 50, 100, or 125 mg/kg, i.p., for 7 days) or duration- (100 mg/kg, i.p., for 0, 1, 3, 5, or 14 days) dependent manner to induce Tat 1-86 in brain. Mice were assessed for anxiety-like behavior in an open field, social interaction, or marble burying task 0, 7, and/or 14 days later. Central expression of Tat 1-86 protein was verified with Western blot analyses. Results Doxycycline produced no effects on C57BL/6J controls that lacked the Tat 1-86 transgene. Among GT-tg mice, doxycycline (100 mg/kg for 3, 5, or 7 days) significantly increased anxiety-like behavior in all tasks, commensurate with enhanced Western blot labeling of Tat 1-86 protein in brain, displaying optimal effects with the 7-day regimen. Greater exposure to doxycycline (either 125 mg/kg for 7 days or 100 mg/kg for 14 days) impaired locomotor behavior; whereas lower dosing (below 100 mg/kg) produced only transient increases in anxiety-like behavior. Conclusions Expression of HIV-1-Tat 1-86 in GT-tg mouse brain produces exposure-dependent, persistent increases in anxiety-like behavior.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>24352568</pmid><doi>10.1007/s00213-013-3385-1</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0033-3158
ispartof Psychopharmacology, 2014-06, Vol.231 (11), p.2349-2360
issn 0033-3158
1432-2072
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4020990
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Animal behavior
Animals
Anxiety
Anxiety Disorders - chemically induced
Anxiety Disorders - physiopathology
Biomedical and Life Sciences
Biomedicine
Blotting, Western
Brain
Brain - drug effects
Brain - physiopathology
Complications and side effects
Development and progression
Dose-Response Relationship, Drug
Doxycycline - pharmacology
Gene Expression - drug effects
Genetic aspects
HIV
HIV infection
Human immunodeficiency virus
Human immunodeficiency virus 1
Male
Mice, Inbred C57BL
Mice, Transgenic
Neuropsychological Tests
Neurosciences
Original Investigation
Pharmacology/Toxicology
Physiological aspects
Proteins
Psychiatry
Psychological aspects
Psychotropic Drugs - pharmacology
Risk factors
Rodents
tat Gene Products, Human Immunodeficiency Virus - genetics
tat Gene Products, Human Immunodeficiency Virus - metabolism
Time Factors
Viral proteins
title Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T15%3A40%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anxiety-like%20behavior%20of%20mice%20produced%20by%20conditional%20central%20expression%20of%20the%20HIV-1%20regulatory%20protein,%20Tat&rft.jtitle=Psychopharmacology&rft.au=Paris,%20Jason%20J.&rft.date=2014-06-01&rft.volume=231&rft.issue=11&rft.spage=2349&rft.epage=2360&rft.pages=2349-2360&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-013-3385-1&rft_dat=%3Cgale_pubme%3EA372250933%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1524245589&rft_id=info:pmid/24352568&rft_galeid=A372250933&rfr_iscdi=true